Figure 1.

Study flow diagram for retrospective, double‐blinded review of patient records. A total of 299 patients with PAH were included in the study. Of the 299 patients with PAH, approximately one‐third were initiated on prostacyclin and two‐thirds were initiated on any PAH‐specific therapy as the latest treatment between January 2014 and March 2017. Risk scores were calculated using REVEAL Lite 2 and COMPERA 2.0 risk assessments and are independent of each other. Thus, some patients may have been categorized into different risk strata based on REVEAL Lite 2 and/or COMPERA 2.0, depending on their specific patient factors. PAH, pulmonary arterial hypertension.